- Align Technology is dedicated to "transforming lives by improving the journey to a healthy, beautiful smile".
- The company has delivered record revenues in Q3, but only on a year-on-year basis, and even when considering the lower range of the guidance, sales for 2021 should beat last year by at least 50%.
- On the other hand, sporadic rise in infections and seasonality impacted sequential growth and variants could sap demand for the Invisalign brand in the short term just as it did last year.
- With better growth, profitability, and debt metrics compared to peers, together with a differentiated business model, Align's higher valuations are justified.
- The stock is a hold for shareholders and a buy-on-the-dip for potential investors.
For further details see:
Align Technology: Looking Behind That Healthy, Beautiful Smile Reveals Long Term Strength